HLB Therapeutics Co Ltd
KOSDAQ:115450
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2.7), the stock would be worth ₩4 528.43 (30% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2 | ₩3 475 |
0%
|
| 3-Year Average | 2.7 | ₩4 528.43 |
+30%
|
| 5-Year Average | 3.3 | ₩5 655.43 |
+63%
|
| Industry Average | 4.6 | ₩7 773.49 |
+124%
|
| Country Average | 1.1 | ₩1 911.76 |
-45%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
H
|
HLB Therapeutics Co Ltd
KOSDAQ:115450
|
306.3B KRW | 2 | -33.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | -106.7 | 83.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 21.2 | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 7 | 18.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 5.8 | 27.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 2.5 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 6.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 2.3 | 30.3 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 0.7 |
| Median | 1.1 |
| 70th Percentile | 2.3 |
| Max | 2 461.2 |
Other Multiples
HLB Therapeutics Co Ltd
Glance View
HLB Therapeutics Co., Ltd. engages in the development and sale of vaccines and manufacture of electronic parts. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2010-03-26. Along with its affiliates, the Company operates solution business segment, which provides embedded graphic user interface (GUI) software solutions as well as wired and wireless integration multimedia platform solutions. Its embedded GUI products include FXUI-two-dimensional (2D), FXUI-three-dimensional (3D) and FX Studio, which are used for cellular phones and embedded equipment. Its wired and wireless integration multimedia platform products include FX-Flash and others, which are used for cellular phones and other mobile devices; electronic components manufacturing business segment, which provides transformers, pumps, motors and others, as well as educational and bio pharmaceutical business segments.
